GLP-1RAS IN OSTEOARTHRITIS Osteoarthritis (OA) is a degenerative joint disease characterized by progressive degradation of the cartilage cushioning the ends of bones, subchondral bone remodeling, and synovial inflammation, leading to joint stiffening and decreased motility[7]
Tirzepatide, meanwhile, combines the effects of both GLP-1 and GIP receptor agonists, offering dual action that may further enhance appetite suppression and metabolic benefits
[1] [2] These medicines include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro), which is a dual GIP/GLP-1 receptor agonist
While this body of evidence is highly encouraging, it is important to note that these findings are derived from studies with considerable methodological heterogeneity, a limitation that will be addressed in the Discussion
What Lifestyle and Diet Changes Are Required While Taking This Medication
An individualized approach is always the way to go when it comes to maintaining wellness
